
195940.KQ Earnings — HK inno.N Corporation
KOE
Updated
When is 195940.KQ's next earnings date?
HK inno.N Corporation (195940.KQ) has not announced its next earnings date yet. Its most recent earnings report was on Wednesday, October 28, 2026.
How did 195940.KQ do in its last earnings report?
In its most recent report on Oct 28, 2026, HK inno.N Corporation posted EPS of $691.60 versus the $594.00 estimate, a beat. Revenue was $260.40B against a $267.52B estimate.
How much does 195940.KQ stock move after earnings?
195940.KQ beat EPS estimates in 1 of its last 2 reported quarters.
About HK inno.N Corporation
Founded in 1984 and headquartered in Cheongju-si, South Korea, HK inno.N Corporation operates as a pharmaceutical enterprise. The company boasts a comprehensive portfolio of prescription medications designed to address a wide array of medical conditions. These include treatments for various infectious diseases, such as those caused by gram-positive and gram-negative bacteria, vancomycin-resistant Enterococcus faecium, acute bacterial sinusitis, bronchitis, and pneumonia. Their therapeutic offerings also extend to chronic illnesses like anemia, diabetes, hypertension (including cases with dyslipidemia), and hypercholesterolemia (covering primary and homozygous familial types), alongside solutions for hemodialysis. The firm develops drugs for gastrointestinal disorders such as GERD, EE, NERD, GU, and H. Pylori infections. In the oncology sector, HK inno.N provides treatments for non-small cell lung cancer, colorectal cancer, and both pleural and general mesothelioma. Additionally, they offer nutritional and intravenous therapeutic solutions. Beyond pharmaceuticals, the corporation supplies health and wellness products, including hangover relief drinks, ready-to-drink beverages, health supplements, functional foods, and active pharmaceutical ingredients. Its beauty division markets products under the bewants, ScalpMed, and KLEDERMA RX brands. The company maintains an international presence, exporting its diverse range of products to markets across Japan, Southeast Asia, Latin America, Europe, and the Middle East.
🤖 AI Earnings Analysis
195940.KQ trades at a modest 11.0× earnings with a 7.12% profit margin; without news or growth data, valuation alone doesn’t establish upside.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | 594.00 | 691.60 | — | $260.40B | ✅ Beat | — | — | — | |
| 2026-07-29 | 721.00 | 482.67 | — | $267.20B | ❌ Miss | — | — | — |
Showing last 2 quarters.